NJIT-EDC Biotechnology Incubator
139 South Street, Suite 102
61 articles with Edge Therapeutics
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Edge Therapeutics, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Edge Therapeutics, Inc. violated federal securities laws.
Shares of Edge Therapeutics were in free fall Wednesday afternoon following the company’s decision to discontinue development of a late stage treatment for adults with aneurysmal subarachnoid hemorrhage (aSAH).
In addition, the company also appointed pharma vet Andrew Saik as CFO.
The conference call will be available via phone and webcast.
Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, To Its Board Of Directors
Edge Therapeutics Announces Conference Call On May 3, 2017 To Discuss First Quarter 2017 Financial Results
Edge Therapeutics Announces First Patient Randomized In Study Of Intracisternal Administration Of EG-1962 In Adults With Aneurysmal Subarachnoid Hemorrhage
Edge Therapeutics Announces Conference Call On March 2, 2017 To Discuss Fourth Quarter And Full Year 2016 Financial Results
Edge Therapeutics Appoints Alyssa Wyant As Senior Vice President, Regulatory Affairs And Makes Inducement Grant Under NASDAQ Rule 5635(C)(4)
Edge Therapeutics Announces Publication Of Phase I/II Data On EG-1962 For The Treatment Of Aneurysmal Subarachnoid Hemorrhage In Peer-Reviewed Medical Journal, Stroke
Edge Therapeutics To Host Conference Call On November 1, 2016 To Discuss Third Quarter Financial Results
Edge Therapeutics Appoints Chief Operating Officer And Makes Inducement Grant Under NASDAQ Rule 5635(c)(4)
Edge Therapeutics To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series And Participate In Additional Investor Conferences In September